|
Randomized phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with single-agent OV versus (vs) gemcitabine (GEM) and P followed by maintenance with single-agent GEM as first-line chemotherapy (CT) in locally advanced (LA) or metastatic non-small-cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pierre Fabre; Roche |
Research Funding - Boehringer Ingelheim |
|
|
Employment - Pierre Fabre |
Stock and Other Ownership Interests - Pierre Fabre |
Research Funding - Pierre Fabre |
Travel, Accommodations, Expenses - Pierre Fabre |
|
|
Employment - Pierre Fabre |
Research Funding - Pierre Fabre |
Travel, Accommodations, Expenses - Pierre Fabre |
|
|
Employment - Pierre Fabre |
Stock and Other Ownership Interests - Pierre Fabre |
Research Funding - Pierre Fabre |
Travel, Accommodations, Expenses - Pierre Fabre |
|
|
Employment - Pierre Fabre |
Stock and Other Ownership Interests - Pierre Fabre |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer |
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Merck Sharp & Dohme; Pfizer; Roche; Teva |
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Merck Sharp & Dohme; Novartis; Pfizer; Roche |